title: Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
abstract: We investigated the clinical efficacy and tolerability of 45 mg/day mosapride, a selective 5-hydroxytryptamine type 4 (5-HT4) agonist, in an open-label study involving five patients with Parkinson's disease (PD) who had response fluctuations (RFs). 'On' time and motor function scores were determined, and gastric motility was measured by a radionuclide gastric emptying (GE) test, the most reliable quantitative method available. We found that mosapride therapy significantly shortened GE half-time, reduced RFs, and improved motor functions in all patients. There were no adverse reactions. We conclude that selective 5-HT4 agonist therapy is beneficial for patients with PD who have RFs.
authors.affiliation: Department of Neurology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. neurohiro@hotmail.com
authors.forename: Hirohide
authors.initials: H
authors.lastname: Asai
authors.forename: Fukashi
authors.initials: F
authors.lastname: Udaka
authors.forename: Makito
authors.initials: M
authors.lastname: Hirano
authors.forename: Takeshi
authors.initials: T
authors.lastname: Minami
authors.forename: Masaya
authors.initials: M
authors.lastname: Oda
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Kubori
authors.forename: Kazuto
authors.initials: K
authors.lastname: Nishinaka
authors.forename: Masakuni
authors.initials: M
authors.lastname: Kameyama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ueno
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000097:blood / Q000493:pharmacokinetics; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects; D005769:Gastrointestinal Motility / Q000502:physiology*; D006801:Humans; D007980:Levodopa / Q000097:blood / Q000493:pharmacokinetics; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D049268:Positron-Emission Tomography; D044422:Receptors, Serotonin, 5-HT4 / Q000187:drug effects*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D013270:Stomach / Q000000981:diagnostic imaging
chemical_list: D000978:Antiparkinson Agents; D001549:Benzamides; D009025:Morpholines; D017366:Serotonin Receptor Agonists; D044422:Receptors, Serotonin, 5-HT4; D007980:Levodopa; C062720:mosapride